TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of ...

Sophie Koonin discusses the realities of large-scale technical migrations, using Monzo’s shift to TypeScript as a roadmap.

A blending of committed youth groups from Fayette County gathered at the Summit Bechtel Reserve last weekend for a special ...

Preview this article 1 min If the company moves forward with the project on a 186-acre site, it could entail more than $1 billion in investment in a growing area of Fort Worth. Get the latest in this ...

Drug-related AEs were reported in 14.1% of participants on DOR/ISL and 18.0% on BIC/FTC/TAF and discontinuations due to AEs (1.1% vs. 2.2%) were similar in both groups. Immune reconstitution was ...

While the company hasn't confirmed its plans, public documents indicate more than 1,400 jobs could be created and tens of millions of dollars could be invested.

Abstract: Faculty websites are often the first entry point for students seeking research opportunities, yet they vary widely in showing inclusive values. We examine how biology faculty websites at ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...

Twelve-month data from the VOLT-AF Global IDE study found that the Volt PFA System had an industry-leading success rate (84.2%) of freedom from documented rhythm recurrence among all competitive PFA ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

BEAVER DAM, Wis. (WKOW)— The city council in Beaver Dam listened to residents' concerns about a proposed data center on Feb. 2. Council members also had the opportunity to ask the data center company ...

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...